Sulfonyl-substituted bicyclic compounds as modulators of ppar

Abstract

Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed.

1 - 13 . (canceled) 
   
   
       14 . A method of modulating a peroxisome proliferator-activated receptor (PPAR) function comprising contacting said PPAR with 4-[2,6-dimethyl-4-(4-trifluoromethoxy-benzyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid. 
   
   
       15 . The method as recited in  claim 24 , contacting said PPAR with a single enantiomer of 4-[cis-2,6-dimethyl-4-(4-trifluoromethoxy-benzyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid substantially free of the other enantiomer. 
   
   
       16 . The method as recited in  claim 24  wherein said modulation is selective for PPARδ over PPARγ or PPARα. 
   
   
       17 . The method as recited in  claim 26  wherein said selectivity is 100-fold or greater. 
   
   
       18 . A method for treating scarring in a patient in need thereof comprising
 i. identifying a patient in need of such treatment; and   ii. administering to said patient a therapeutically effective amount of a therapeutically effective amount of 4-[2,6-dimethyl-4-(4-trifluoromethoxy-benzyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid.   
   
   
       19 . A method for treating scarring in a patient in need thereof comprising
 i. identifying a patient in need of such treatment; and   ii. administering to said patient a therapeutically effective amount of a single enantiomer of 4-[cis-2,6-dimethyl-4-(4-trifluoromethoxy-benzyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid substantially free of the other enantiomer.   
   
   
       20 . A method of wound healing in a patient in need thereof comprising
 i. identifying a patient in need of wound healing; and   ii. administering to said patient a therapeutically effective amount of 4-[2,6-dimethyl-4-(4-trifluoromethoxy-benzyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid.   
   
   
       21 . A method of wound healing in a patient in need thereof comprising
 i. identifying a patient in need of wound healing; and   ii. administering to said patient a therapeutically effective amount of a single enantiomer of 4-[cis-2,6-dimethyl-4-(4-trifluoromethoxy-benzyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid substantially free of the other enantiomer.   
   
   
       22 . A method for treating an inflammatory disease in a patient in need thereof comprising
 i. identifying a patient in need of such treatment; and   ii. administering to said patient a therapeutically effective amount of 4-[2,6-dimethyl-4-(4-trifluoromethoxy-benzyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid.   
   
   
       23 . The method as recited in  claim 22 , wherein said disease is selected from the group consisting of asthma, rheumatoid arthritis, osteoarthritis, inflammatory response to tissue injury, psoriasis, ulcerative colitis, dermatitis, and autoimmune disease. 
   
   
       24 . The method as recited in  claim 23 , wherein said disease is inflammatory response to tissue injury. 
   
   
       25 . A method for treating an inflammatory disease in a patient in need thereof comprising
 i. identifying a patient in need of such treatment; and   ii. administering to said patient a therapeutically effective amount of a single enantiomer of 4-[cis-2,6-dimethyl-4-(4-trifluoromethoxy-benzyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid substantially free of the other enantiomer.   
   
   
       26 . The method as recited in  claim 25 , wherein said disease is selected from the group consisting of asthma, rheumatoid arthritis, osteoarthritis, inflammatory response to tissue injury, psoriasis, ulcerative colitis, dermatitis, and autoimmune disease. 
   
   
       27 . The method as recited in  claim 26 , wherein said disease is inflammatory response to tissue injury. 
   
   
       28 . A method for treating, in a patient in need thereof, a disease selected from the group consisting of diabetes, obesity, metabolic syndrome, and insulin resistance, comprising
 iii. identifying a patient in need of such treatment; and   iv. administering to said patient a therapeutically effective amount of a therapeutically effective amount of 4-[2,6-dimethyl-4-(4-trifluoromethoxy-benzyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid.   
   
   
       29 . The method as recited in  claim 28  wherein said disease is diabetes. 
   
   
       30 . The method as recited in  claim 28  wherein said disease is obesity. 
   
   
       31 . The method as recited in  claim 28  wherein said disease is metabolic syndrome. 
   
   
       32 . The method as recited in  claim 28  wherein said disease is insulin resistance. 
   
   
       33 . A method for treating, in a patient in need thereof, a disease selected from the group consisting of diabetes, obesity, metabolic syndrome, and insulin resistance, comprising
 iii. identifying a patient in need of such treatment; and   iv. administering to said patient a therapeutically effective amount of a single enantiomer of 4-[cis-2,6-dimethyl-4-(4-trifluoromethoxy-benzyl)-piperazine-1-sulfonyl]-indan-2-carboxylic acid substantially free of the other enantiomer.   
   
   
       34 . The method as recited in  claim 33  wherein said disease is diabetes. 
   
   
       35 . The method as recited in  claim 33  wherein said disease is obesity. 
   
   
       36 . The method as recited in  claim 33  wherein said disease is metabolic syndrome. 
   
   
       37 . The method as recited in  claim 33  wherein said disease is insulin resistance.